Adhesion molecules in primary oral mucosal melanoma: Study of claudins, integrins and immunoglobulins in a series of 35 cases

American Journal of Dermatopathology

Volumn 35, Issue 5, 2013, Pages 541-554

  Bologna, Sheyla Batista ^a   Nico, Marcello Menta S ^a   Hsieh, Ricardo ^a   Coutinho Camillo, Cláudia Malheiros ^b   Buim, Marcilei E ^b   Fernandes, Juliana Dumet ^c   Sangueza, Martin ^d   Soares, Fernando Augusto ^a,b   Lourenço, Silvia Vanessa ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b A C CAMARGO CANCER CENTER   (Brazil)

^c FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^d Hospital Obrero   (Bolivia)

Author keywords

adhesion molecules; oral melanoma; tissue microarray

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; BETA3 INTEGRIN; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE; CELL ADHESION MOLECULE; CLAUDIN; IMMUNOGLOBULIN; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CD66; CHILD; CLINICAL ARTICLE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; MALE; MELANOMA; MOUTH CANCER; NEWBORN; ORAL MUCOSA MELANOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOPSY; BOLIVIA; BRAZIL; CELL ADHESION MOLECULES; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; CLAUDINS; FEMALE; HUMANS; IMMUNOGLOBULINS; IMMUNOHISTOCHEMISTRY; INFANT; INFANT, NEWBORN; INTEGRINS; MALE; MELANOMA; MIDDLE AGED; MOUTH MUCOSA; MOUTH NEOPLASMS; NECROSIS; NEOPLASM GRADING; NEOPLASM INVASIVENESS; PROGNOSIS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84880569985     PISSN: 01931091     EISSN: 15330311     Source Type: Journal    
DOI: 10.1097/DAD.0b013e318276cab3     Document Type: Article

References (65)

1. Prasad ML, Patel SG, Huvos AG, et al. Primary mucosal melanoma of the head and neck. A proposal for microstaging localized, stage I (lymph node-negative) tumours. Cancer. 2004;100:1657-1664.
2. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma. A summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1998; 83:1664-1678.
3. Liversedge RL. Oral malignant melanoma. Br J Oral Surg. 1975:13: 40-55.
4. Shah JP, Huvos AG, Strong EW. Mucosal melanomas of the head and neck. Am J Surg. 1977;134:531-535.
5. Snow GB, van der Esch EP, van Slooten EA. Mucosal melanomas of the head and neck. Head Neck Surg. 1978;1:24-30.
6. Moran WJ. Melanoma of the upper aerodigestive tract: a review of 21 cases. Head Neck Surg. 1986;8:309-312.
7. Trapp TK, Fu YS, Calcaterra TC. Melanoma of the nasal and paranasal sinus mucosa. Arch Otolaryngol Head Neck Surg. 1987;113: 1086-1089.
8. Matias C, Corde J, Soares J. Primary malignant melanoma of the nasal cavity. A clinicopathologic study of nine cases. J Surg Oncol. 1988;39: 29-32.
9. Franquemont DW, Mills SE. Sinonasal malignant melanoma. A clinicopathologic and immunohistochemical study of 14 cases. Am J Clin Pathol. 1991;96:689-697.
10. Friedman RJ, Rigel DS, Kopf AW, et al. Volume of malignant melanoma is superior to thickness as a prognostic indicator: preliminary observation. Dermatol Clin. 1991;9:643-648.
11. Patel SG, Prasad ML, Escrig M, et al. Primary mucosal malignant melanoma of the head and neck. Head Neck. 2002;24:247-257.
12. RicardoHsieh R, Nico MMS, Coutinho-Camillo CM, et al. The CDKN2A and MAP Kinase pathways: molecular roads to primary oral mucosal melanoma. Am J Dermatopathol. In press.
13. Palmieri G, Capone M, Ascierto ML, et al. Main roads to melanoma. J Trans Med. 2009;7:86.
14. Gaggioli C, Sahai E. Melanoma invasion-current knowledge and future directions. Pigment Cell Res. 2007;20:161-172.
15. Shih IM, Speicher D, Hsu MY, et al. Melanoma cell-cell interactions are mediated through heterophilic Mel-CAM/ligand adhesion. Cancer Res. 1997;57:3835-3840.
16. Haass NK, Smalley KSM, Li L, et al. Adhesion, migration and communication in melanocytes and melanoma. Pigment Cell Res. 2005;18:150-159.
17. van der Flier A, Sonnenberg A. Function and interactions of integrins. Cell Tissue Res. 2001;305:285-298.
18. Rathinam R, Alahari SK. Important role of integrins in the cancer biology. Cancer Metastasis Rev. 2010;29:223-237.
19. Kuphal S, Bauer R, Bosserhoff AK. Integrin signaling in malignant melanoma. Cancer Met Rev. 2005;24:195-222.
20. Cavallaro U, Dejana E. Adhesion molecule signaling: not always a sticky business. Nat Rev Mol Cell Biol. 2011;12:189-197.
21. Sawada N, Murata M, Kikuchi K, et al. Tight junctions and human diseases. Med Electron Microsc. 2003;36:147-156.
22. Cohn ML, Goncharuk VN, Diwan AH, et al. Loss of claudin-1 expression in tumor-Associated vessels correlates with acquisition of metastatic phenotype in melanocytic neoplasms. J Cutan Pathol. 2005;32:533-536.
23. Langbein L, Pape UF, Grund C, et al. Tight junction-related structures in the absence of a lumen: occludin, claudins and tight junction plaque proteins in densely packed cell formations of stratified epithelia and squamous cell carcinomas. Eur J Cell Biol. 2003;82:385-400.
24. Billings SD, Walsh SV, Fisher C, et al. Aberrant expression of tight junction-related proteins ZO-1, claudin-1 and occludin in synovial sarcoma: an immunohistochemical study with ultrastructural correlation. Mod Pathol. 2004;17:141-149.
25. Kominsky SL, Argani P, Korz D, et al. Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene. 2003;22: 2021-2033.
26. Lourenço SV, Coutinho-Camilo CM, Buim ME, et al. Claudin-7 down-regulation is an important feature in oral squamous cell carcinoma. Histopathology. 2010;57:689-698.
27. Lourenço SV, Coutinho-Camillo CM, Buim ME, et al. Oral squamous cell carcinoma: status of tight junction's claudins in the different histopathological patterns and relationship with clinical parameters. A tissue microarray based study of 136 cases. J Clin Pathol. 2010;63:609-614.
28. Michl P, Barth C, Buchholz M, et al. Claudin-4 expression decreases invasiveness and metastatic potencial of pancreatic cancer. Cancer Res. 2003;63:6265-6271.
29. Sato N, Fukushima N, Maitra A, et al. Gene expression profiling identifies genes associated with invasive intraductal papillary mucinous neoplasms of the pancreas. Am J Pathol. 2004;164:903-914.
30. Rangel LB, Agarwal R, D'Souza T, et al. Tight junction proteins claudin- 3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res. 2003;9:2567-2575.
31. Thies A, Schachner M, Moll I, et al. Overexpression of the cell adhesion molecule L1 is associated with metastasis in cutaneous malignant melanoma. Eur J Cancer. 2002;38:1708-1716.
32. Denton KJ, Stretch JR, Gatter KC, et al. A study of adhesion molecules as markers of progression in malignant melanoma. J Pathol. 1992;167: 187-191.
33. Johnson JP, Bar EM, Jansen B, et al. Melanoma progression-Associated glycoprotein MUC18/MCAM mediates homotypic cell adhesion through interaction with a heterophilic ligand. Int J Cancer. 1997;73: 769-774.
34. Natali P, Nicotra MR, Cavaliere R, et al. Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions. Cancer Res. 1990;50:1271-1278.
35. Schlagbauer WH, Jansen B, Muller M, et al. Influence of MUC18/ MCAM/CD146 expression on human melanoma growth and metastasis in SCID mice. Int J Cancer. 1999;81:951-955.
36. Lourenço SV, A Martin Sangueza, Sotto MN, et al. Primary oral mucosal melanoma: a series of 35 new cases from South America. Am J Dermatopathol. 2009;31:323-330.
37. Hynes RO. Integrins: bidirectional, allosteric signalingmachines. Cell. 2002;110:673-687.
38. Moretti S, Martini L, Berti E, et al. Adhesion molecule profile and malignancy of melanocytic lesions. Melanoma Res. 1993;3:235-239.
39. Yoshinaga IG, Vink J, Dekker SK, et al. Role of alpha 3 beta 1 and alpha 2 beta 1 integrins in melanoma cell migration. Melanoma Res. 1993;3:435-441.
40. Zhu N, Eves PC, Katerinaki E, et al. Melanoma cell attachment, invasion, and integrin expression is upregulated by tumor necrosis factor alpha and suppressed by alpha melanocyte stimulating hormone. J Invest Dermatol. 2002;119:1165-1171.
41. Heino J, Ignotz RA, Hemler ME, et al. Regulation of cell adhesion receptors by transforming growth factor-B. J Biol Chem. 1989;164: 380-388.
42. Mortarini R, Anichini A. From adhesion to signalling: roles of integrins in the biology of human melanoma. Melanoma Res. 1993;3:87-97.
43. Danen EH, Van Muijen GN, Ruiter DJ. Role of integrins as signal transducing cell adhesion molecules in human cutaneous melanoma. Cancer Surv. 1995;24:43-65.
44. Johnson RC, Fenn NJ, Horgan K, et al. Follow-up of patients with a thin melanoma. Br J Surg. 1999;86:619-621.
45. Seftor RE, Seftor EA, Hendrix MJ. Molecular role(s) for integrins in human melanoma invasion. Cancer Metastasis Rev. 1999;18:359-375.
46. McGary EC, Lev DC, Bar-Eli M. Cellular adhesion pathways and metastatic potential of human melanoma. Cancer Biol Ther. 2002;1:459-465.
47. Albelda SM, Mette SA, Elder DE, et al. Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. Cancer Res. 1990;50:6757-6764.
48. Schadendorf D, Gawlik C, Haney U, et al. Tumour progression and metastatic behaviour in vivo correlates with integrin expression on melanocytic tumours. J Pathol. 1993;170:429-434.
49. Natali PG, Hamby CV, Felding-Habermann B, et al. Clinical significance of alpha(v)beta3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions. Cancer Res. 1997;57: 1554-1560.
50. Bachmann IM, Ladstein RG, Straume O, et al. Tumor necrosis is associated with increased alphavbeta3 integrin expression and poor prognosis in nodular cutaneous melanomas. BMC Cancer. 2008;8:362.
51. Neto DS, Pantaleão L, de Sá BC, et al. Alpha-v-beta3 integrin expression in melanocytic nevi and cutaneous melanoma. J Cutan Pathol. 2007;34: 851-856.
52. Danen EH, Ten Berge PJ, Van Muijen GN, et al. Emergence of alpha 5 beta 1 fibronectin- and alpha v beta 3 vitronectin-receptor expression in melanocytic tumour progression. Histopathology. 1994;24:249-256.
53. Agarwal R, Mori Y, Cheng Y, et al. Silencing of claudin-11 is associated with increased invasiveness of gastric cancer cell. Plos One. 2009;4: e8002.
54. Matsuda M, Kubo A, Furuse M, et al. A peculiar internalization of claudins, tight juntion-specific adhesion molecules during the intercellular movement of epithelial cells. J Cell Sci. 2004;117(Pt 7):1247-1257.
55. Leotlela PD, Wade MS, Duray PH, et al. Claudin-1 overexpression in melanoma is regulated by PKC and contributes to melanoma cell motility. Oncogene. 2007;26:3846-3856.
56. French AD, Fiori JL, Camilli TC, et al. PKC and PKA phosphorylation affect the subcellular localization of claudin-1 in melanoma cells. Int J Med Sci. 2009;6:93-101.
57. Lehmann JM, Riethmüller G, Johnson JP. MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc Natl Acad Sci USA. 1989;86:9891-9895.
58. Johnson JP, Rummel MM, Rothbächer U, et al. MUC18: A cell adhesion molecule with a potential role in tumor growth and tumor cell dissemination. Curr Top Microbiol Immunol. 1996;213(pt 1): 95-105.
59. Shih IM, Elder DE, Hsu MY, et al. Regulation of Mel-CAM/MUC18 expression on melanocytes of different stages of tumor progression by normal keratinocytes. Am J Pathol. 1994;145:837-845.
60. Xie K, Wang Y, Huang S, et al. Nitric oxide-mediated apoptosis of K-1735 melanoma cells is associated with downregulation of Bcl-2. Oncogene. 1997;15:771-779.
61. Swart GW, Lunter PC, Kilsdonk JW, et al. Activated leukocyte cell adhesion molecule (ALCAM/CD166): signaling at the divide of melanoma cell clustering and cell migration? Cancer Met Rev. 2005;24:223-236.
62. van Kempen LC, van den Oord JJ, van Muijen GN, et al. Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin. Am J Pathol. 2000;156: 769-774.
63. Schadendorf D, Heidel J, Gawlik C, et al. Association with clinical outcome of expression of VLA-4 in primary cutaneous malignant melanoma as well as P-selectin and E-selectin on intratumoral vessels. J Natl Cancer Inst. 1995;87:366-371.
64. Miele ME, Bennett CF, Miller BE, et al. Enhanced metastatic ability of TNF-Alpha-treated malignant melanoma cells is reduced by intercellular adhesion molecule-1 (ICAM-1, CD54) antisense oligonucleotides. Exp Cell Res. 1994;214:231-241.
65. Thies A, Moll I, Berger J, et al. CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease. J Clin Oncol. 2002;20:2530-2536.